Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- China Emerges as a Key Destination for New Clinical Trials in 2018: Informa Report
November 8, 2019
- Japan Market Logs Hefty 8.9% Growth in July-September: IQVIA
November 8, 2019
- AstraZeneca’s COPD Triplet Promotion Stands Out in August: Impact Track
November 8, 2019
- Keytruda Stays on Top in October Japan Drug Ranking: Encise
November 8, 2019
- Takeda’s Dengue Vaccine Candidate Showed Confirmed Protection Efficacy in PIII
November 8, 2019
- As Trintellix Debut Nears, Lundbeck Japan Morphing into Full-Fledged Commercial Company
November 7, 2019
- 3rd Conditional Approval Candidate Was DMD Drug Viltolarsen, Nippon Shinyaku Reveals
November 7, 2019
- Takeda Acquires Rights to CAR NK Cell Therapies from MD Anderson
November 7, 2019
- Takeda Opens New Dengue Vaccine Manufacturing Facility in Germany
November 7, 2019
- 8 Japan Majors Log Combined Sales Rise in 1st Half on Shire Buy, Solid Earnings at Home
November 6, 2019
- Fairly Good If Gilenya Royalty Issue Could Be Settled in 2 Years: Mitsubishi Chemical CFO
November 6, 2019
- Treakisym Succeeds in PIII DLBCL Study, Japan Filing Eyed in H1 2020: SymBio
November 6, 2019
- Takeda to Divest Non-Core Assets Sold in Russia, Former Soviet States
November 6, 2019
- Daiichi Sankyo Sues Seattle Genetics over ADC Technology
November 6, 2019
- Eisai Transfers Tazemetostat Royalty Rights Outside Japan to US Firm
November 6, 2019
- Crysvita Accepted for Review in Europe for Additional Adult Use
November 6, 2019
- Torii Acquires Japan Marketing Rights to BioCryst’s HAE Treatment
November 6, 2019
- Boehringer Japan to Support Pharmacists and Nurses to Improve Treatment of COPD
November 5, 2019
- Boehringer Japan Aims to Maintain Top Combined COPD Market Share for LAMA/LABA Combos, LAMA Monodrugs
November 5, 2019
- Roivant Wants to Validate Its Biz Model with Commercial Success of Sumitomo Dainippon Alliance: CEO
November 5, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…